-
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan’s team at the Third People’s Hospital of Jiangsu University conducted research on the impact of NAFLD, as confirmed by liver histopathology, and pathological changes on individuals with chronic HBV infection. The latest research…
-
President Doctor Shuichiro Shiina Invites You to Attend the 2024 the Asian Pacific Association for the Study of the Liver Conference in Kyoto, Japan
At the 58th European Association for the Study of the Liver (EASL) Annual Meeting, also known as EASL 2023 Congress, Professor Shuichiro Shiina, the President of the Asian Pacific Association…
-
Dr. Yanhua Ding’s Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation
Dr. Yanhua Ding’s Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation Yanhua Ding practices in Changchun, China. Ding and is rated as an Experienced expert by MediFind in the treatment of Arthritis. They are also highly rated in 3 other conditions, according to our data. Their top…
-
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France. Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation).…
-
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress Tom Hemming Karlsen (MD, PhD) is a clinical specialist in internal medicine and gastroenterology working in Oslo, Norway. Dr. Karlsen graduated from medical school at the University of Bergen in 1997. In 2012 he…
-
Treatment Options for Early Liver Cancer, Strategies for Preventing Recurrence, and the Application of New Molecular Technologies in Tumour
Early treatment is the key to improving the survival rate of liver cancer patients. At the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Fabio Piscaglia from the University of Bologna, Italy, presented the latest developments in the treatment of early-stage hepatocellular…
-
New Insights from EASL: The Role of Lifestyle Interventions in Preventing and Treating NAFLD/NASH in Children and Adults
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease globally and is independently associated with an increased risk of Type 2 Diabetes (T2DM) and cardiovascular diseases. Approximately one-third of the global population is currently facing the health threat posed by NAFLD, yet it appears that healthcare systems are not giving it enough…
-
Dr. Jinlin Hou and Dr. Fan Rong’s Team: The Joint Application of aMAP Score and LSM Provides a New Strategy for Liver Fibrosis Assessment in Untreated
The assessment of liver fibrosis in patients with chronic hepatitis B (CHB) is of significant importance for initiating antiviral treatment and evaluating treatment efficacy. Serum models represented by Fibrosis-4 index (FIB-4) and aspartate transaminase-to-platelet ratio index (APRI) exhibit inconsistent diagnostic performance for liver fibrosis in different study populations. Moreover, there is controversy regarding whether the…
Connecting Medical Expertise through Media